[18F]FDG代谢肿瘤体积作为神经内分泌肿瘤预后标志物的多中心研究
该多中心回顾性研究纳入231例晚期胃肠胰神经内分泌肿瘤患者,以平扫SUV阈值4半自动勾画[18F]FDG PET/CT的代谢肿瘤体积(MTV),按中位数16.5 cm3分为高、低MTV组。高MTV组中位总生存期较短(23.8个月 vs 未达到;HR 2.49;95%CI 1.69-3.66;P<0.0001),且MTV与分级均为独立预后因素。
要点
- 高MTV组中位总生存期23.8个月,低MTV组未达到(HR 2.49;95%CI 1.69-3.66;P<0.0001)。
- 高MTV组中位治疗失败时间较短(11.7个月 vs 16.9个月;HR 1.52;95%CI 1.13-2.06;P=0.005)。
- 多因素分析中仅分级(P=0.001)和MTV(P<0.001)为独立预后因素。
核心结论
- MTV是晚期胃肠胰神经内分泌肿瘤的预后生物标志物。
- 作者认为[18F]FDG PET报告除描述[18F]FDG摄取程度外,或可从MTV注释中获益。
研究设计与样本
- 多中心回顾性研究,纳入既往建立队列中接受[18F]FDG PET/CT的晚期胃肠胰神经内分泌肿瘤患者。
- 图像来自3个中心,采用统一方案采集,以平扫SUV阈值4使用半自动软件工作流程勾画并核实。
- 主要终点为总生存期,按MTV中位数将患者二分高MTV组和低MTV组,采用log-rank检验和多因素分析比较总生存期。
主要发现
- 共纳入231例患者(49%男性;中位年龄60岁)。
- 原发部位:胰腺45%、小肠42%、其他部位13%;世界卫生组织2019分级:1级23%、2级52%、3级21%、分级未知4%。
- 中位随访27个月(四分位距11-49个月),中位总生存期38.6个月。
- 高MTV组中位总生存期较短(切点16.5 cm3;23.8个月 vs 未达到;HR 2.49;95%CI 1.69-3.66;P<0.0001)。
- 高MTV组中位治疗失败时间较短(11.7个月 vs 16.9个月;HR 1.52;95%CI 1.13-2.06;P=0.005);组织学分级升高与MTV升高相关(P=0.0006,单因素方差分析)。
关键数值与推荐
- MTV勾画采用平扫SUV阈值4。
- 按MTV中位数16.5 cm3将患者分为高MTV组和低MTV组。
临床怎么用
- 作者认为[18F]FDG PET在胃肠胰神经内分泌肿瘤中的报告除[18F]FDG摄取程度外,或可从MTV注释中获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
[18F]FDG PET/CT avidity predicts higher-grade disease and worse prognosis in patients with metastatic neuroendocrine neoplasm. However, there is less evidence regarding the role of [18F]FDG-avid tumor volume in predicting prognosis. We planned to determine whether metabolic tumor volume (MTV) on [18F]FDG PET/CT predicts prognosis in patients with advanced gastroenteropancreatic neuroendocrine neoplasm (GEPNEN). Methods: A multicenter retrospective study was performed on patients with advanced GEPNEN who underwent [18F]FDG PET/CT in a previously established cohort. Images were acquired across 3 centers using harmonized protocols and were contoured and verified at a flat SUV threshold of 4 using a semiautomated software workflow. The primary endpoint was overall survival. Patients were dichotomized into high- and low-MTV groups by the median value, with the overall survival of the 2 resulting cohorts compared by log-rank tests and multivariate analyses. Results: In total, 231 patients were included (49% male; median age, 60 y). In 45% of cases the primary was the pancreas, in 42% the small bowel, and in 13% another location. Regarding World Health Organization 2019 grade, 23% were grade 1, 52% grade 2, 21% grade 3, and 4% an unknown grade. The median follow-up was 27 mo (interquartile range, 11-49 mo), and median overall survival was 38.6 mo. Median overall survival was shorter in the high-MTV cohort than in the low-MTV cohort (cut point, 16.5 cm3; 23.8 mo vs. not reached; hazard ratio, 2.49; 95% CI, 1.69-3.66; P < 0.0001). Median time to treatment failure was also shorter in the high-MTV cohort (11.7 mo vs. 16.9 mo; hazard ratio, 1.52; 95% CI, 1.13-2.06; P = 0.005). Increasing histologic grade was associated with higher MTV (P = 0.0006, 1-way ANOVA). Multivariate analysis incorporating age, grade, sex, SUVmax, and MTV showed that only grade (P = 0.001) and MTV (P < 0.001) were independently prognostic. Conclusion: MTV is a prognostic biomarker in advanced GEPNEN. Reports of [18F]FDG PET in GEPNEN may benefit from comments on MTV in addition to the degree of [18F]FDG avidity.
引用
- Chan DL, Hayes A, Karfis I, et al. [18F]FDG Metabolic Tumor Volume as a Prognostic Marker in Neuroendocrine Neoplasm: A Multicenter Study. J Nucl Med. 2025. PMID: 40404400. doi:10.2967/jnumed.124.269031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。